lopinavir/ritonavir - for COVID-19   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death or transfer to ICU 1.09 [0.99, 1.20]< 10%1 study (1/-)4.0 %some concernnot evaluable moderatecrucial-
deaths 1.02 [0.91, 1.13]< 10%6 studies (6/-)38.2 %some concernnot evaluable moderatecrucial-
clinical improvement 0.67 [0.28, 1.60]> 185%3 studies (3/-)18.6 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.20 [0.46, 3.13]> 180%2 studies (2/-)64.5 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.59 [0.84, 3.03]> 10%1 study (1/-)92.1 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 3.16 [0.62, 16.06]> 10%1 study (1/-)91.7 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 0.61 [0.12, 3.01]> 192%2 studies (2/-)27.2 %some concernnot evaluable moderateimportant-
clinical worsening 3.69 [0.37, 36.57]< 10%1 study (1/-)13.4 %some concernnot evaluable moderateimportant-
hospital discharge 0.98 [0.91, 1.05]> 10%1 study (1/-)29.0 %some concernnot evaluable moderateimportant-
PCR-negative conversion 0.43 [0.08, 2.20]> 161%2 studies (2/-)15.7 %some concernnot evaluable moderateimportant-
PCR-negative conversion (14-day) 0.92 [0.80, 1.06]> 10%2 studies (2/-)12.2 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 0.73 [0.37, 1.43]> 12%2 studies (2/-)18.0 %some concernnot evaluable moderateimportant-
PCR-negative conversion (time to event analysis only) 0.23 [0.10, 0.54]> 10%1 study (1/-)0.0 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 0.75 [0.53, 1.06]> 10%2 studies (2/-)4.9 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.10 [0.00, 2.09]> 10%1 study (1/-)7.2 %some concernnot evaluable moderateimportant-

-- safety endpoints 00

serious adverse events 0.75 [0.16, 3.48]< 129%2 studies (2/-)64.5 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 3 pathologies: 87,95,94,90,91,97 95, 91, 90